Who Paid My Doc
Montaser Shaheen
Hematology San Antonio, TX Medical Doctor
NPI 1801860168 CMS profile 585400
7979 Wurzbach Rd Ste 2222, San Antonio, TX 78229
General payments
$75,043
Research payments
$2,630
Ownership & investment interest
$0
Research they led as principal investigator
$3,277,447
Through program year 2025, Montaser Shaheen of San Antonio, TX is reported in the CMS Open Payments database as having received $75,043 across 80 general payments and $2,630 in research payments paid to them. Separately, studies naming them as principal investigator received $3,277,447 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 84th percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | Research | $2,630 | 1 | |
| 2022 | General | $184 | 5 | |
| 2021 | General | $1,955 | 2 | |
| 2020 | General | $1,403 | 6 | |
| 2019 | General | $71,502 | 67 |
Beside peers
- Montaser Shaheen
- Hematology median
- Middle half of Hematology
- National median
In program year 2025, general payments to Montaser Shaheen were reported at $0. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.
Show as a table
| Year | Montaser Shaheen | Hematology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $71,502 | $1,012 | $122–$9,834 | $163 |
| 2020 | $1,403 | $1,475 | $115–$9,198 | $114 |
| 2021 | $1,955 | $1,470 | $125–$7,444 | $132 |
| 2022 | $184 | $1,371 | $139–$8,471 | $149 |
| 2023 | $0 | $1,295 | $147–$11,010 | $160 |
| 2024 | $0 | $1,286 | $146–$9,230 | $164 |
| 2025 | $0 | $1,155 | $135–$8,023 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
350
Drug cost
$3,396,430
Branded share of claims
42.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cabometyx Cabozantinib S-Malate | Brand | 99 | $2,583,873 | |
| Welireg Belzutifan | Brand | 12 | $351,049 | |
| Inlyta Axitinib | Brand | 12 | $257,084 | |
| Xtandi Enzalutamide | Brand | 14 | $201,144 | |
| Hydrocortisone | Generic | 23 | $1,278 | |
| Synthroid Levothyroxine Sodium | Brand | 12 | $596 | |
| Methylprednisolone | Generic | 30 | $252 | |
| Doxepin Hcl | Generic | 16 | $234 | |
| Anastrozole | Generic | 18 | $197 | |
| Bicalutamide | Generic | 16 | $192 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 799 Part D prescribers listed as Hematology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 111 billing codesPaid by Medicare
$1,561,961
Medicare patients
245
Services billed
59,707
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 62% | |
| Arthritis | 40% | |
| Diabetes | 39% | |
| Chronic kidney disease | 37% | |
| Ischemic heart disease | 31% | |
| Depression | 24% | |
| Atrial fibrillation | 21% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 21 | 9,800 | $438,535 |
| Injection, nivolumab, 1 mg J9299 | Office | 18 | 15,020 | $372,233 |
| Injection, denosumab, 1 mg J0897 | Office | 11 | 1,860 | $38,926 |
| Injection, fosaprepitant, 1 mg J1453 | Office | 11 | 3,300 | $384 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 12 | 230 | $173 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 33 | 666 | $60 |
| Infusion, normal saline solution, 250 cc J7050 | Office | 17 | 70 | $34 |
| Injection, ondansetron hydrochloride, per 1 mg J2405 | Office | 22 | 364 | $27 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 21 | 40 | $26 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
81 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology in Texas
Related records
Hematology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Hematology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.